Wilson Sonsini Goodrich & Rosati advised Verona Pharma on patent matters on the deal. Verona Pharma plc (Nasdaq: VRNA) announced that the U.S. Food and Drug...
Verona Pharma’s US FDA Approval of Ohtuvayre™
Radar Therapeutics’ $13.4 Million Seed Funding Round
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Radar Therapeutics on the deal, and Wilson Sonsini Goodrich & Rosati advised Radar Therapeutics on IP matters related...
Karius’ $100 Million Series C Financing Round
Wilson Sonsini Goodrich & Rosati advised Karius on IP matters related to the transaction. Karius®, Inc. (Karius), a world leader in genomic diagnostics for infectious disease,...
Verve Therapeutics’ Relationship Expansion with Lilly
Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on IP matters related to the transaction. Verve Therapeutics, Inc. (Nasdaq:VERV) announced the expansion of its relationship with Eli Lilly...
Adela’s $48 Million Financing Round
Wilson Sonsini Goodrich & Rosati advised Adela on patent matters related to the transaction. Adela, Inc. announced the completion of a $48 million financing. The round included existing...
Verve Therapeutics’ Collaboration Agreement with Lilly
Wilson Sonsini Goodrich & Rosati advised Verve on IP matters related to the transaction. Verve Therapeutics, Inc., a clinical-stage genetic medicines company, announced an exclusive research collaboration...
Foresight Diagnostics’ $58.75 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Foresight on the deal. Foresight Diagnostics, Inc, a leading developer of ultrasensitive cancer detection tests, announced the close of an...
Cognito Therapeutics’ $73 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Cognito on the transaction. Neurotechnology company Cognito Therapeutics announced a $73 million Series B financing round. The financing was led...
EpiBiologics’ $50 Million Series A Financing
Wilson Sonsini advised EpiBiologics on the deal. EpiBiologics, a biotechnology company building a next-generation antibody-based protein degradation platform for membrane and extracellular drug targets, launched with...
GE HealthCare’s Acquisition of Caption Health
Wilson Sonsini Goodrich & Rosati advised Caption Health on the acquisition. GE HealthCare, a leading global precision care innovator, announced that it has signed an agreement...
Bruker’s Acquisition of Inscopix
Wilson Sonsini Goodrich & Rosati advised Inscopix on the deal. Bruker Corporation, a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions,...
Roche’s Acquisition of Good Therapeutics
Wilson Sonsini advised Good Therapeutics on the deal. Good Therapeutics, a privately held company founded to create a new class of conditionally active therapeutics, announced it...